How much did Innovega raise on SeedInvest?
Apr 02, 2022 · InnovAge Stock Forecast, Price & News $6.55 -0.04 (-0.61%) (As of 04/14/2022 12:00 AM ET) Today's Range $6.38 $6.61 50-Day Range $4.11 $6.77 52-Week Range $3.46 $26.44 Volume 63,685 shs Average Volume 375,486 shs Market Capitalization $887.64 million P/E Ratio 218.33 Dividend Yield N/A Beta N/A Profile Analyst Ratings Chart Competitors
Do analysts agree on InnovAge's (INOV) stock's price target?
Get notified regarding key financial metrics and revenue changes at Innovega Learn more. Summary - Funding Rounds. Founding Date: 2008: Total Funding: $4.2 m: Investors: Tencent Holdings: In total, Innovega had raised $4.2 m. ... Common Stock: 2.0m: Retained Earnings (2.9m) Total Equity (866.0k) Innovega Cash Flow. Annual. THB FY, 2018 ...
Where can I buy Innoviva shares?
Find the latest Innoviva, Inc. (INVA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Who owns InnovAge stock?
Mar 29, 2022 · Innoviva Stock Forecast, Price & News $19.28 -0.16 (-0.82%) (As of 04/13/2022 12:43 PM ET) Today's Range $19.17 $19.61 50-Day Range $15.40 $20.25 52-Week Range $11.15 $20.71 Volume 9,137 shs Average Volume 1.19 million shs Market Capitalization $1.34 billion P/E Ratio 6.94 Dividend Yield N/A Beta 0.44 Profile Analyst Ratings Chart Competitors
What is the stock symbol for Innovega?
INNVCommon Stock (INNV)
Why is InnovAge stock dropping?
The catalyst for the downgrades was InnovAge's disclosure last week that it had been hit with sanctions from the Centers for Medicare and Medicaid Services (CMS).
Should I buy InnovAge stock?
There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" InnovAge stock.
What market cap means?
Market cap—or market capitalization—refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares. For example, a company with 20 million shares selling at $50 a share would have a market cap of $1 billion.
What happened to InnovAge?
InnovAge said the sanctions were "based on deficiencies detected in an audit that was conducted earlier this year the final results which have not yet been disclosed to the company." As a result of this development, InnovAge has withdrawn its 2022 guidance.Dec 27, 2021
Is InnovAge a non profit?
In addition to its scale, InnovAge stands out from other PACE providers as a for-profit entity. Hewitt led the organization's conversion from a nonprofit to a for-profit in 2016, following changes in regulation from CMS and the state of Colorado. One goal of the conversion was to access capital more readily.Mar 7, 2021
Will innovage stock go up?
On average, Wall Street analysts predict that INNOVAGE HOLDING's share price could reach $11.30 by Dec 28, 2022. The average INNOVAGE HOLDING stock price prediction forecasts a potential upside of 86.47% from the current INNV share price of $6.06.
Does market cap include cash?
I've always viewed cash as not being included in market cap, but if you think about DCF analysis, the market cap or equity value of a company is really just the present value of cash flows generated by the business, including the cash currently on the balance sheet.
How is the stock price calculated?
After a company goes public, and its shares start trading on a stock exchange, its share price is determined by supply and demand for its shares in the market. If there is a high demand for its shares due to favorable factors, the price will increase.
Is a higher market cap better?
Generally, market capitalization corresponds to a company's stage in its business development. Typically, investments in large-cap stocks are considered more conservative than investments in small-cap or midcap stocks, potentially posing less risk in exchange for less aggressive growth potential.
Is InnovAge a buy right now?
8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InnovAge in the last twelve months. There are currently...
How were InnovAge's earnings last quarter?
InnovAge Holding Corp. (OTCMKTS:INNV) issued its earnings results on Tuesday, February, 8th. The company reported $0.04 EPS for the quarter, missin...
What price target have analysts set for INNV?
8 Wall Street analysts have issued 12 month price objectives for InnovAge's shares. Their forecasts range from $4.00 to $27.00. On average, they ex...
Who are InnovAge's key executives?
InnovAge's management team includes the following people: Ms. Maureen Hewitt , Pres, CEO & Director (Age 60, Pay $1.63M) ( LinkedIn Profile ) Ms...
Who are some of InnovAge's key competitors?
Some companies that are related to InnovAge include Privia Health Group (PRVA) , U.S. Physical Therapy (USPH) , Sharecare (SHCR) , Sema4 (SMFR)...
What other stocks do shareholders of InnovAge own?
Based on aggregate information from My MarketBeat watchlists, some companies that other InnovAge investors own include EEStor Co. (ESU.V) (ESU) ,...
What is InnovAge's stock symbol?
InnovAge trades on the OTCMKTS under the ticker symbol "INNV."
Who are InnovAge's major shareholders?
InnovAge's stock is owned by many different retail and institutional investors. Top institutional investors include Coliseum Capital Management LLC...
Which major investors are selling InnovAge stock?
INNV stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Deutsche Bank...
Is Innoviva a buy right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating for...
How has Innoviva's stock price been impacted by COVID-19?
Innoviva's stock was trading at $12.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since...
When is Innoviva's next earnings date?
Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, April 27th 2022. View our earnings forecast for Innoviva .
How were Innoviva's earnings last quarter?
Innoviva, Inc. (NASDAQ:INVA) issued its earnings results on Wednesday, February, 9th. The biotechnology company reported $0.55 EPS for the quarter,...
What price target have analysts set for INVA?
1 Wall Street analysts have issued 1 year target prices for Innoviva's stock. Their forecasts range from $12.00 to $12.00. On average, they anticip...
Who are Innoviva's key executives?
Innoviva's management team includes the following people: Pavel Raifeld , Chief Executive Officer Marianne Zhen , Chief Accounting Officer
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Amgen (AMGN) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) , Vertex Pharmaceu...
What other stocks do shareholders of Innoviva own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO...
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
What is the Entasis pipeline?
Entasis’ pipeline includes sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant Acinetobacter baumannii infections, and zoliflodacin for uncomplicated gonorrhea, including infection s caused by drug-resistant strains of Neisseria gonorrhoeae .
How much did Innoviva buy in 2021?
The stock purchase will occur in two closings. At the initial closing, which occurred on May 3, 2021, Innoviva purchased approximately 3.7 million shares of common stock and warrants to purchase approximately 3.7 million shares of common stock for an aggregate purchase price of approximately $7.5 million.
What was the net loss for 2021?
Research and development expenses were $9.4 million during the three months ended March 31, 2021, compared to $11.6 million during the three months ended March 31, 2020.
When will the second tranche of the IRA close?
The closing of the first tranche of the financing, consisting of approximately $7.5 million, occurred on May 3, 2021. The closing of the second tranche, consisting of approximately $12.5 million, is expected to occur in early June, assuming approval of the financing at a special meeting of stockholders.
Is Armata a biotechnology company?
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Company's $20 million private placement of its common stock with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) (together, "Innoviva"). In connection with the second closing, Armata issued 4,285,935 common shares and 4,285,935 warrants with an exercise price of $3.25 per share, at a per unit price of $3.25 per unit, in exchange for gross proceeds of approximately $13.9 million. Approximately 99% of the Armata shares represented and voting at the special meeting of shareholders voted in favor of the transaction.
How much does Innoviva make?
How much money does Innoviva make? Innoviva has a market capitalization of $1.35 billion and generates $336.79 million in revenue each year. The biotechnology company earns $224.40 million in net income (profit) each year or $2.37 on an earnings per share basis.
Who owns Innoviva stock?
Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.04%). Company insiders that own Innoviva stock include George Bickerstaff, Innoviva, Inc and Plc Glaxosmithkline. View institutional ownership trends for Innoviva.
Is Innoviva a sell or buy?
Wall Street analysts have given Innoviva a " Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Innoviva wasn't one of them.
What is emacula eyewear?
Innovega created eMacula®, a wearable display system that includes patented disposable smart contact lenses and a portfolio of display eyewear. This combination satisfies the wearers’ demand for light-weight stylish eyewear and access to high-quality media. The eMacula display eyewear system can deliver high-resolution media with as large as 110-degrees field of view.
How much did Global Ophthalmic Consultants pay in 2020?
During the period ended September 30, 2020, the Company paid Global Ophthalmic Consultants, LLC $38,790. As of the period ending September 30, 2020, the Company had no outstanding amounts due, or receivables from, Global OphthalmicConsultants, LLC. *Please refer to Offering Circular for full list of Risk Factors.
How many people in the US need vision correction?
Over 60% of persons in the U.S. and over 70% in Asia require vision correction. Innovega’s patented contact lenses include prescription correction for real-world vision while simultaneously enabling the wearer to view high-performance media in micro-displays located in stylish eyewear.
What is an offering circular?
The offering circular is the legal document filed with the SEC for a Regulation A offering and provides facts that an investor needs to make an informed investment decision. The offering circular includes an overview of company and company's business, historical financials and capitalization, and key risk factors.
What is Steve Jobs' degree?
Steve passionately pursues the development of game-changing, disruptive technologies and products. He holds graduate degrees in engineering, graphics, and business. Steve founded and co-founded multiple companies that achieved exits through acquisitions or IPO.
Do contact lenses need approval?
Contact lenses require regulatory clearance or approval. Contact lenses are regulated medical devices and require a market clearance or an approval from regulatory bodies. Our contact lens is worn during the waking hours and removed before sleep. Management expects it to be classified as a daily wear contact lens.
Who is Steve Willey?
Steve Willey, CEO, and Co-founder of Innovega, has been interested in display eyewear since the early 1980’s when he co-founded a video game company. He realized that graphics quality determined player enjoyment.
Innovega Comparisons
lit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sun
Innovega Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
What causes vision loss in a 26 year old?
The subjects ranged from age 26-76 with a range of causes of vision loss that included albinism, Stargardt disease, myopic degeneration, histoplasmosis, optic and age-related macular degeneration (AMD). Distance Acuity.
How much will digital magnification cost in 2025?
The global assisted technologies market is expected to grow to US D 6.57 billion by 2025.*
How much will the AR/VR market be in 2024?
Subject to availability of lightweight, smart glasses, Digi-Capital forecasts AR/VR global market to grow from over $13 billion in 2020 to more than $67 billion by 2024* and with an installed base of tens of millions of wearers.
Private Investing: The Least Efficient Market
Have you ever watched a stock candlestick chart and thought, “why can’t I know what comes next too?” Companies like Apple (NASDAQ: AAPL) have more than 40 Wall Street analysts tracking their every move; many will predict next quarter’s earnings down to the penny.
Private Investing
Private investing has been around nearly as long as finance itself. Small business owners routinely raise money from family and friends to get started. And wealthy investors — whether Renaissance-era bankers in Venice or modern day Silicon Valley angel investors — have provided capital for some of the most cutting-edge companies of their time.
Helix Power
Helix Power seeks to create energy storage by using flywheels. The firm has already received $2.3 million in grant funding, and now seeks a seed round of $1 million to test a full-scale system by Q1 2022. The minimum investment is $1,000.
Matcherino
Pardon the strange name — Matcherino is one of the stars when it comes to esports. The company runs a software platform that hosts esports events, and already powers over a thousand tournaments a month. Investment minimums start at $1,000, and its $13 million pre-money valuation offers room for 1,000x growth.
i2Chain
The Colonial Pipeline hack this past spring made painfully obvious a fact technologists have long known: your data isn’t safe anymore.
The Downside to Private Investing
There is one downside to private investing: there’s no one telling you whether something is a bad idea.
The Troubles at Innovega
First, eagle-eyed investors will quickly realize that Innovega doesn’t show a working model on its SeedInvest page. Nor does the company share plans on how they will project images onto the contact lenses and glasses. It’s a problem that Innovega founder Stephen Willey has been working on since 1993 when he started MicroVision (NASDAQ: MVIS ).